Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia
- PMID: 3282032
- DOI: 10.1200/JCO.1988.6.4.583
Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia
Abstract
The value of maintenance therapy after the achievement of complete remission in adult acute nonlymphocytic leukemia (ANLL) has never been clearly established. A randomized Eastern Cooperative Oncology Group (ECOG) study of postremission therapy compared outcomes in patients who received no further therapy to those administered long-term maintenance chemotherapy. Adverse results in the group administered no further therapy led to early termination of this trial after only 51 patients were randomized. Patients receiving no postremission therapy experienced significantly inferior remission durations (P = .002) compared with patients receiving maintenance therapy. All 26 patients in the group administered no postremission therapy have relapsed, with a median duration of remission of 4.1 months. In contrast, four of 25 patients (16%) who received maintenance therapy remain disease free, with a median duration of remission of 8.1 months.
Similar articles
-
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.Leukemia. 1989 Feb;3(2):115-21. Leukemia. 1989. PMID: 2911205 Clinical Trial.
-
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.J Clin Oncol. 1984 Aug;2(8):865-70. doi: 10.1200/JCO.1984.2.8.865. J Clin Oncol. 1984. PMID: 6379120 Clinical Trial.
-
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.J Clin Oncol. 1998 Mar;16(3):872-81. doi: 10.1200/JCO.1998.16.3.872. J Clin Oncol. 1998. PMID: 9508168 Clinical Trial.
-
Therapy in childhood acute nonlymphocytic leukemia (ANLL). Evolution of current concepts of chemotherapy.Am J Pediatr Hematol Oncol. 1981 Winter;3(4):379-88. Am J Pediatr Hematol Oncol. 1981. PMID: 6174052 Review.
-
Adult acute nonlymphocytic leukemia.Med Clin North Am. 1984 May;68(3):675-95. doi: 10.1016/s0025-7125(16)31122-1. Med Clin North Am. 1984. PMID: 6379338 Review.
Cited by
-
Optimal Post-Remission Consolidation Therapy in Patients with AML.Acta Haematol. 2024;147(2):147-158. doi: 10.1159/000535457. Epub 2023 Nov 26. Acta Haematol. 2024. PMID: 38008085 Free PMC article. Review.
-
More than two courses of pre-transplant consolidation therapy benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study.Chin Med J (Engl). 2023 Aug 5;136(15):1855-1863. doi: 10.1097/CM9.0000000000002347. Chin Med J (Engl). 2023. PMID: 36730715 Free PMC article.
-
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).Ann Hematol. 2014 Jan;93(1):47-55. doi: 10.1007/s00277-013-1940-9. Epub 2013 Oct 23. Ann Hematol. 2014. PMID: 24149914 Free PMC article.
-
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.Am J Hematol. 2019 Jul;94(7):803-811. doi: 10.1002/ajh.25484. Epub 2019 May 1. Am J Hematol. 2019. PMID: 30945331 Free PMC article. Review.
-
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19. Future Oncol. 2016. PMID: 26785287 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
